---
layout: default
title: Erlotinib
parent: 僅模型預測 (L5)
nav_order: 258
evidence_level: L5
indication_count: 0
---

# Erlotinib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

The `data-report` skill doesn't apply here — this task is generating a structured evaluation report from a provided JSON, not presenting CLI output. I'll proceed directly with the Drug Repurposing Evaluation Report (v5) format.

---

# Erlotinib: Drug Repurposing Evaluation — Incomplete Evidence Pack

## One-Sentence Summary

Erlotinib (DB00530) is a small-molecule oncology agent known from public literature as an EGFR tyrosine kinase inhibitor, but its original indications are not populated in this Evidence Pack and it holds no current Taiwan regulatory approvals in the system.
This Evidence Pack contains **no TxGNN-predicted new indications**, no mechanism of action data, and all safety fields are absent, making a standard repurposing assessment impossible at this stage.
The recommended action is **Hold** — evaluation cannot proceed until Data Gaps DG001 (Blocking) and DG002 (High) are resolved and TxGNN predictions are generated.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not populated in this Evidence Pack |
| Predicted New Indication | Not available — TxGNN output pending |
| TxGNN Prediction Score | Not available |
| Evidence Level | N/A |
| Taiwan Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN predicted indications are currently available for Erlotinib in this Evidence Pack. The prediction pipeline has not yet produced repurposing candidates for DB00530, so mechanistic reasoning cannot be anchored to a specific target indication.

Detailed mechanism of action data is also absent (Data Gap DG002). Based on publicly available information, Erlotinib is a reversible inhibitor of the epidermal growth factor receptor (EGFR / HER1 / ErbB-1) tyrosine kinase and has established oncology use in EGFR-mutant non-small cell lung cancer and advanced pancreatic cancer. However, this background cannot substitute for structured Evidence Pack data in a formal repurposing evaluation.

Once `predicted_indications` are populated and MOA data is loaded from DrugBank (DB00530), this section can be completed with a full mechanistic rationale and indication-to-indication bridging analysis.

---

## Clinical Trial Evidence

Currently no related clinical trials registered — no predicted indication is available to search against.

---

## Literature Evidence

Currently no related literature available — no predicted indication is available to search against.

---

## Taiwan Market Information

No Taiwan regulatory authorizations are on record in this Evidence Pack.

| Item | Detail |
|------|--------|
| Market Status | 未上市 (Not Marketed) |
| Total DINs | 0 |

> **Verification Note:** Erlotinib (Tarceva®) is approved and in clinical use across multiple jurisdictions internationally. If a zero-DIN result is unexpected for the Taiwan context, please cross-check directly against the TFDA official database — this may reflect a data ingestion gap in the pipeline rather than actual non-availability in the market.

---

## Cytotoxicity

Erlotinib is an antineoplastic targeted therapy. This section is included because the drug belongs to the oncology/cancer treatment category (EGFR tyrosine kinase inhibitor class).

| Item | Content |
|------|---------|
| Cytotoxicity Classification | Targeted therapy — EGFR tyrosine kinase inhibitor (not conventional cytotoxic) |
| Myelosuppression Risk | Low — bone marrow suppression is not a primary toxicity mechanism for EGFR-TKIs |
| Emetogenicity Classification | Low to moderate |
| Monitoring Items | Liver function (AST/ALT/bilirubin), renal function, pulmonary status (interstitial lung disease / pneumonitis), skin toxicity (acneiform rash, paronychia), electrolytes |
| Handling Protection | Please refer to the package insert warnings and precautions; standard oncology handling protocols apply |

---

## Safety Considerations

Please refer to the package insert for safety information.

> Safety data has not yet been ingested into this Evidence Pack. Resolution requires downloading and parsing the TFDA package insert PDF (Data Gap DG001, Blocking severity) before any safety-based evaluation can be conducted.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Two unresolved data gaps — DG001 (TFDA warnings/contraindications, **Blocking**) and DG002 (mechanism of action, **High**) — prevent entry into the safety screening stage, and the absence of any `predicted_indications` means there is no repurposing candidate to evaluate at all. No assessment can be completed in the current state.

**To proceed, the following is needed:**

- **[Blocking — DG001]** Download the TFDA package insert PDF for Erlotinib and parse it to populate `key_warnings` and `contraindications`
- **[High — DG002]** Query the DrugBank API for Erlotinib (DB00530) to populate `original_moa` and pharmacological target data
- **[Critical]** Re-run the TxGNN prediction pipeline for Erlotinib to generate `predicted_indications`; without this output, no repurposing report can be written
- **[Verify]** Cross-check Taiwan regulatory status against the TFDA official database to confirm whether the 0-DIN result reflects a true non-registration or a pipeline ingestion failure
- **[Nice to have]** Populate `original_indications` from DrugBank or TFDA records to enable indication-bridging analysis once predictions are available
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

